CIR for different NPM1^mut/ABL1 cutoffs after completion of treatment with conventional chemotherapy and autologous SCT through follow-up. CIR analyzed by Gray’s regression model was affected by increasing MRD burden. CIR was calculated for the following NPM1^mut/ABL1 cutoffs: (A) 0.01%, (B) 1%, (C) 1% and FLT3-ITD status, (D) 2%, (E) 5%, and (F) 10%.